Table 3 Antibiotic regimens
From: 2017 WSES and SICG guidelines on acute calcolous cholecystitis in elderly population
a. Antimicrobial therapy for community-acquired cholecystitis | ||
Choice | Antibiotic class (Best choice from 1 to 5) | Antibiotic choice |
1 | Beta-lactam/beta-lactamase inhibitor combinations based regimens | Amoxicillin/Clavulanate (in stable patients) Ticarcillin/Clavulanate (in stable patients) Piperacillin/Tazobactam (in unstable patients) |
2 | Cephalosporins-based regimens | Ceftriazone + Metranidazole (in stable patients) Cefepime + Metranidazole (in unstable patients) |
3 | Carbapenem-based regimens | Ertapenem (in stable patients if risk factors for ESBLs) |
4 | Fluoroquinolone-based regimens (in case of allergy to beta-lactams) | Ciprofloxacin + Metronidazole (only in stable patients) Levofloxacin + Metronidazole (only in stable patients) Moxifloxacin (only in stable patients) |
5 | Glycylcycline-based regimen | Tigecycline (in stable patients if risk factors for ESBLs) |
b. Antimicrobial therapy for heath care-associated | ||
Clinical patient’s condition | Antibiotic choice | |
Stable | Tigecycline + Piperacillin/Tazobactam | |
Unstable | Imipenem/Cilastatin ± Teicoplanin | |
Meropenem ± Teicoplanin | ||
Doripenem ± Teicoplanin | ||